Looking back at the very impressive presentation of 2012 I'm...

Looking back at the very impressive presentation of 2012 I'm curious as to why PAT-SC1 is still in the licensing out stage.

The presentation (April 2012?) noted a "significant 10 year survival benefit for 30 patients with minimal residual disease".

Also there was reference to: Out-licensing with a Japanese Consultant. I'm assuming that because gastric cancer is higher in Japan than America/Europe, that the Japanese would be jumping out of their skins to license a product with such promising data, but there you go...

Perhaps the recent trial announcement with Amgen might finally crystalize a deal on this front? I'm not sure of the size of the potential market for gastric cancer but it's likely much smaller than that of MM and melanoma, but all the same a deal should come with a reasonable up-front if PAB can ever get a signature; it just goes to show just how difficult it is to attract the interest of big pharma, no matter how good your product might be.